公开(公告)号：US11590158B2

公开(公告)日：2023-02-28

申请号：US17463391

申请日：2021-08-31

Applicant: Novartis AG

Inventor： Christoph Bucher ,  Dietmar Flubacher ,  Jeremiah Douglas Foutch ,  Malay Ghosh ,  Johannes Franz Kluge ,  Zaixing Li ,  Cale Ry McAlister ,  Liladhar Murlidhar Waykole ,  Jens Sören Worthmann ,  Tingying Zhu

IPC: A61K31/724 ,  C07C309/72 ,  A61K31/381 ,  A61K47/02 ,  A61K47/38 ,  C07D339/04

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

公开(公告)号：US20210393671A1

公开(公告)日：2021-12-23

申请号：US17463391

申请日：2021-08-31

Applicant: Novartis AG

Inventor： Christoph Bucher ,  Dietmar Flubacher ,  Jeremiah Douglas Foutch ,  Malay Ghosh ,  Johannes Franz Kluge ,  Zaixing Li ,  Cale Ry McAlister ,  Liladhar Murlidhar Waykole ,  Jens Sören Worthmann ,  Tingying Zhu

IPC: A61K31/724 ,  A61K47/02 ,  A61K47/38 ,  C07D339/04 ,  A61K31/381 ,  C07C309/72

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

公开(公告)号：US10174006B2

公开(公告)日：2019-01-08

申请号：US14292082

申请日：2014-05-30

Applicant: Novartis AG

Inventor： Malay Ghosh ,  Christopher Michael Adams ,  Stephanie Kay Dodd ,  Stephen Hedrick Poor

IPC: A61K31/55 ,  A61K31/519 ,  A61K31/506 ,  A61K31/4439 ,  A61K31/724 ,  C07D403/12 ,  C07D401/12 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D519/00 ,  A61K9/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K9/08 ,  A61K47/38

Abstract: The present invention is directed to the provision of a multi-dose topical ophthalmic composition containing a 1H-indole-1-carboxamide and use thereof for treatment of ophthalmic disease. More specifically the present invention is directed to a multi-dose aqueous ophthalmic composition (e.g., a solution, a suspension, an emulsion or the like) containing a 1H-indole-1-carboxamide (e.g., N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide) and use thereof for treatment of an ophthalmic disease at the back of the eye such as age related macular degeneration (AMD).

公开(公告)号：US20140364392A1

公开(公告)日：2014-12-11

申请号：US14292082

申请日：2014-05-30

Applicant: Novartis AG

Inventor： Malay Ghosh ,  Christopher Michael Adams ,  Stephanie Kay Dodd ,  Stephen Hedrick Poor

IPC: C07D403/12 ,  A61K31/55 ,  A61K31/519 ,  A61K31/506 ,  A61K31/4439 ,  C07D519/00 ,  C07D413/14 ,  C07D403/14 ,  C07D487/04 ,  C07D471/04 ,  C07D495/04 ,  A61K31/724 ,  C07D401/12

CPC classification number: C07D403/12 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/519 ,  A61K31/55 ,  A61K31/724 ,  A61K47/02 ,  A61K47/10 ,  A61K47/186 ,  A61K47/26 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  C07D401/12 ,  C07D403/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04 ,  C07D519/00

Abstract: The present invention is directed to the provision of a multi-dose topical ophthalmic composition containing a 1H-indole-1-carboxamide and use thereof for treatment of ophthalmic disease. More specifically the present invention is directed to a multi-dose aqueous ophthalmic composition (e.g., a solution, a suspension, an emulsion or the like) containing a 1H-indole-1-carboxamide (e.g., N-(1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6-((methylamino) methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide) and use thereof for treatment of an ophthalmic disease at the back of the eye such as age related macular degeneration (AMD).

Abstract translation: 本发明涉及提供含有1H-吲哚-1-甲酰胺的多剂量局部眼用组合物及其用于治疗眼科疾病的用途。 更具体地说，本发明涉及含有1H-吲哚-1-甲酰胺（例如，N-（1-甲基-5-甲氧基苯基） - （三氟甲基）-1H-吡唑-3-基）-5 - （（6 - （（甲基氨基）甲基）嘧啶-4-基）氧基）-1H-吲哚-1-甲酰胺）及其用于治疗 眼后部的眼部疾病如年龄相关性黄斑变性（AMD）。

公开(公告)号：US20210283171A1

公开(公告)日：2021-09-16

申请号：US17199736

申请日：2021-03-12

Applicant: Novartis AG

Inventor： Christoph Bucher ,  Dietmar Flubacher ,  Jeremiah Douglas Foutch ,  Malay Ghosh ,  Johannes Franz Kluge ,  Zaixing Li ,  Cale Ry McAlister ,  Liladhar Murlidhar Waykole ,  Jens Sören Worthmann ,  Tingying Zhu

IPC: A61K31/724 ,  A61K31/381 ,  C07D339/04 ,  C07C309/72 ,  A61K47/38 ,  A61K47/02

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.

公开(公告)号：US11135239B1

公开(公告)日：2021-10-05

申请号：US17199736

申请日：2021-03-12

Applicant: Novartis AG

Inventor： Christoph Bucher ,  Dietmar Flubacher ,  Jeremiah Douglas Foutch ,  Malay Ghosh ,  Johannes Franz Kluge ,  Zaixing Li ,  Cale Ry McAlister ,  Liladhar Murlidhar Waykole ,  Jens Sören Worthmann ,  Tingying Zhu

IPC: A61K31/724 ,  A61K31/381 ,  C07D339/04 ,  A61K47/38 ,  A61K47/02 ,  C07C309/72

Abstract: The present disclosure provides salts of lipoic acid choline ester (LACE), crystalline forms thereof, and methods of use thereof. The present disclosure further provides pharmaceutical compositions of LACE salts and methods of use thereof.